A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors

Trial Profile

A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Ipatasertib (Primary) ; Docetaxel; Enzalutamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 31 Oct 2017 to 29 Jun 2018.
    • 21 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 29 Jun 2018.
    • 22 Mar 2017 Trial focus has been changed from AR to TU and AR.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top